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Abstract
Background: Colorectal cancer is the second most common cause of cancer related death in the
developed world. To date, no blood or stool biomarkers with both high sensitivity and specificity
for potentially curable early stage disease have been validated for clinical use. SELDI and MALDI
profiling are being used increasingly to search for biomarkers in both blood and urine. Both
techniques provide information predominantly on the low molecular weight proteome (<15 kDa).
There have been several reports that colorectal cancer is associated with changes in the serum
proteome that are detectable by SELDI and we hypothesised that proteomic changes would also
be detectable in urine.
Results: We collected urine from 67 patients with colorectal cancer and 72 non-cancer control
subjects, diluted to a constant protein concentration and generated MALDI and SELDI spectra. The
intensities of 19 peaks differed significantly between cancer and non-cancer patients by both t-tests
and after adjusting for confounders using multiple linear regressions. Logistic regression classifiers
based on peak intensities identified colorectal cancer with up to 78% sensitivity at 87% specificity.
We identified and independently quantified 3 of the discriminatory peaks using synthetic stable
isotope peptides (an 1885 Da fragment of fibrinogen and hepcidin-20) or ELISA (β2-microglobulin).
Conclusion: Changes in the urine proteome may aid in the early detection of colorectal cancer.
Background
Colorectal cancer is the third most common cancer in the
developed world and the second most common cause of
cancer-related death. The prognosis is clearly related to the
stage at which the disease is detected and this observation
has led to screening programmes using the faecal occult
blood test that have resulted in a significant reduction in
mortality [1]. Other stool-based approaches, such as DNA
testing [2] are showing promise but blood tests, such as
carcinoembryonic antigen (CEA) have been disappoint-
ing due to their low sensitivity in patients with early dis-
ease, the target population in screening programmes. The
application of other serum biomarkers such as MMP-9,
complement C3a des-arg and α-defensins [3-5] or pro-
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teomic approaches that seek characteristic diagnostic sig-
natures [6] have met with limited success but have shown
that, in principle, they are capable of generating sensitivi-
ties and specificities that are superior to CEA.
Surface Enhanced Laser Desorption/Ionisation time-of-
flight mass spectrometry (SELDI) has been widely applied
to serum and plasma in attempts to discover changes in
the proteome diagnostic for human cancers (reviewed in
[7-9]). This methodology uses on-chip retentate chroma-
tography followed by Matrix Assisted Laser Desorption/
Ionisation (MALDI) time-of-flight mass spectrometry to
generate spectra or 'proteomic profiles' of biological flu-
ids. The SELDI 'ProteinChip Arrays' used in profiling stud-
ies are typically immobilised metal ion (IMAC) or ion
exchange surfaces. A more flexible approach is to pre-frac-
tionate or de-salt using IMAC, reverse phase or ion
exchange beads (e.g. ref [10]). The intensities of the peaks
in the resulting mass spectra can be compared between
patient cohorts and changes associated with disease state
used to build diagnostic models. Early studies using this
technology attempted to achieve discrimination by iden-
tifying 'signatures' characteristic of specific disease groups
(e.g. [11]) whereas more recent studies have attempted to
identify the polypeptides to which these peaks correspond
to enable immunoassays to be developed. It is important
that experiments are well designed and executed to avoid
any systematic bias between the cohorts being compared
other than specific disease status [7,12]. Our group [6]
and others [13-17] have used SELDI and MALDI to show
that colorectal cancer causes detectable changes in the
serum proteome. Some of the peaks with altered intensi-
ties in colorectal cancer patients have been identified as α-
defensins, apolipoprotein C1, complement C3a des-arg,
α1-antitrypsin and transferrin [6,13].
Tumour-related proteolytic activity, associated with tissue
invasion and migration [18,19], might result in disease
specific patterns of proteolytic fragments and these, being
small (<15 kDa) may be detectable by mass spectrometry.
The proteolytic fragments of interest are likely however to
be present at very low concentrations and effectively
masked by abundant serum proteins (albumin, immu-
noglobulins, etc). We therefore decided to seek such frag-
ments in urine, effectively a natural ultra-filtrate of serum
with the large abundant serum proteins excluded. SELDI
studies on urine have shown that good quality spectra can
be obtained from urine and that renal, bladder and pros-
tate cancers produce proteomic changes [20-26]. More
recently, Ye et al reported proteomic changes in the urine
of ovarian cancer patients [27].
This report is a first attempt to detect colorectal cancer
associated changes in urine by proteomic profiling. We
collected urine from 67 colorectal cancer patients and 72
non-cancer controls. The cancer patient group consisted
of 40 individuals with 'early disease' (Dukes stage A or B
i.e. neoplasia confined to the gut wall) and 27 individuals
with 'late disease' (Dukes C or D i.e. lymph node involve-
ment or distant metastases). Samples were normalised
with respect to protein concentration and, following trials
of different MALDI and SELDI methods using a pooled
sample, were assayed by MALDI with/without de-salting
and Cu2+ loaded IMAC ProteinChip Arrays. We find a
number of proteomic changes that may have utility in the
diagnosis of colorectal cancer.
Methods
Patient Information
Ethical approval for this study was granted by the South
Birmingham LREC (05/Q2702/17). All subjects gave
informed consent, were fasted overnight and midstream
urine was then collected between 9 am and midday. Sam-
ples were kept on ice and transferred to the laboratory
within 5 hours, centrifuged at 3000 rpm for 20 min, aliq-
uotted and stored at -80°C. Individuals below 40 or above
90 years old were excluded from the study as were samples
with a protein concentration of <20 μg protein per ml (14
individuals) or >500 μg protein per ml (5 individuals) as
assessed by the bicinchonninic acid protein assay (Pierce).
After exclusions we retained 139 samples (72 controls and
67 patients, Table 1).
Proteomic Profiling
Prior to profiling urine samples were diluted to 20 μg pro-
tein/ml with deionised water. SELDI and MALDI spectra
were acquired on a PBSIIc ProteinChip reader calibrated
with ACTH, insulin, ubiquitin, cytochrome C, myoglobin
and albumin.
MALDI spectra of neat urine were obtained by applying 1
μl of 20 μg/ml sample to 3 random positions on Gold-
Table 1: Patient Information.
No. Subjects Mean age (SD) Mean [protein] (μg/ml) (SD) Male/Female Stage (Early/Late)
Non-cancer controls 72 66.3 (11.5) 90 (66) 36/36 na
Colorectal cancer patients 67 74.2 (9.0) 108 (79) 45/22 40/27
Table 1 shows the number of individuals in each group, their gender and the mean age and urine protein concentration and cancer stage (early = 
Dukes' A & B, late = Dukes' C & D). Patients whose urine was <20 μg protein per ml (14 individuals) or >500 μg protein per ml (5 individuals) have 
been excluded.Proteome Science 2008, 6:19 http://www.proteomesci.com/content/6/1/19
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Chips followed by air drying and overlaying with 1 μl of
saturated sinapinic acid in 50% acetonitrile/49.5% water/
0.5% TFA. Data were collected up to m/z 20,000 and spec-
tra represent the average of 480 laser shots. MALDI spectra
were also obtained following de-salting on ClinProt C8
magnetic beads (BrukerDaltronic) by mixing urine (80 μl
of 20 μg/ml) with 20 μl of 5% trifluoroacetic acid contain-
ing 2.5 μl of C8 beads and shaking for 5 min. Following
two washes with 0.1% TFA the bound material was eluted
with 15 μl of saturated sinapinic acid in 50% acetonitrile/
49.5% water/0.5% TFA and 1 μl applied to 3 random
positions on GoldChips.
SELDI spectra were obtained using Cu2+ loaded IMAC30
ProteinChip arrays and a 96-well bioprocessor as
described previously [28]. The 20 μg/ml samples were
mixed 1:1 (1 M NaCl, 200 mM sodium phosphate (pH
7.0)) and 100 μl of this mix added to each well in the bio-
processor. Binding was allowed to proceed for 30 min at
room temperature with shaking at 900 rpm. The Protein-
Chip arrays were then washed 4 times using 200 μl of 500
mM NaCl, 100 mM sodium phosphate (pH 7.0) (5 min
with shaking) followed by a water rinse. The chips were
allowed to dry and 2 × 1 μl of a 50% saturated solution of
sinapinic acid in 50% acetonitrile/49.5% water/0.5% TFA
applied to each spot. Data were collected over m/z 0–
20,000 and 0–200,000 ranges (480 laser shot each). All
samples were processed once in random order and then a
second time, again in random order.
Data Analysis
Spectra were normalised to total ion current and baselines
subtracted using Ciphergen ProteinChip software. Peaks
were detected and clustered using Biomarker Wizard soft-
ware (default settings except for a requirement for a peak
to be detected in more than 5% of the samples). Pair wise
correlation coefficients were calculated for the peak inten-
sities of experimental replicates. The MALDI spectra were
obtained in triplicate and the replicate with the poorest
correlation with the other two replicates was discarded.
The peak intensities for the remaining experimental repli-
cates were then averaged prior to further analysis. Samples
which did not produce 2 spectra with a regression coeffi-
cient higher than 0.94 (MALDI) or 0.84 (SELDI) were
excluded from the analyses. Following this QC procedure
the number of individuals in each dataset was: MALDI:
123 (55 cancer), MALDI-DS: 119 (53 cancer), SELDI: 116
(55 cancer), with 105 individuals represented in all 3
datasets. Two-sample t-tests and multiple linear regres-
sion models (LM) were used to identify cancer associated
changes in peak intensities using log (base 2) transformed
data (the t-tests test for a difference in means of the 2
groups whereas the LM tests for an association with cancer
rather than age, gender, protein concentration or sample
collector). For the peaks that showed significance in both
statistical tests the multiple fractional polynomials
method (MFP) [29] was used to determine optimal (lin-
ear/non-linear) relationships between peak intensities
and the presence or absence of colorectal cancer and the
combinations of transformed peaks that lead to improve-
ments in discrimination. The transformed data was then
used for class prediction by logistic regression (LR). Leave-
one-out cross-validation was used to estimate classifica-
tion errors. LM, MFP and LR were carried out using the lm,
mfp and glm objects of R statistical package [29].
Identification of putative biomarkers
The polypeptides underlying the peaks of interest were
purified and identified by tandem mass spectrometry. The
purifications were monitored at each step by MALDI or
SELDI. The initial step in the purifications was to harvest
peptides and proteins from 10–50 ml of urine using C18
SPE cartridges (Phenomenex). Trifluoroacetic acid (TFA)
was added to the urine to a concentration of 0.5% v/v
prior to binding and proteins eluted sequentially with 10,
20, 30 and 40% v/v acetonitrile in water/0.1%TFA. This
was followed by anion exchange fractionation as
described previously [6]. Briefly, the sample was dissolved
in 50 mM Tris/HCl (pH 9) and applied to Q Ceramic
HyperD F anion exchange resin (Pall). Proteins were
eluted sequentially at pH 7, 5, 4 and 3. This was followed
by reverse phase HPLC (4.6 by 150 mm C18, Phenom-
enex)) in 0.1% TFA and proteins eluted using an ace-
tonitrile gradients tailored for each purification (based on
the SPE). Polypeptides <3 kDa were analysed directly by
liquid chromatography tandem mass spectrometry (LC-
MS/MS). Polypeptides >3 kDa were subjected to SDS-
PAGE (12% NuPAGE, MES running buffer, Invitrogen)
and the bands with appropriate mobility excised and
digested with trypsin prior to LC-MS/MS) [28]. We used a
ThermoFinnigan LCQ Deca XP Plus Ion-Trap linked
directly to an LC Packings/Dionex Ultimate nanobore
HPLC system to identify peptides by LC-MS/MS. Data was
filtered using Xcorr values of 1.5, 2 and 2.5 for singly, dou-
bly and triply charged parent ions respectively and only
first hits were considered. MS/MS data was searched
against the IPI human database (version 3.36) using
SEQUEST. Further evidence for the identifications was
obtained by accurate mass determinations of peptides
(ProTOF 2000 orthogonal time-of-flight MALDI mass
spectrometer) or using an immuno-MS approach as previ-
ously described [6,28,30].
Results
Establishing Profiling Conditions
A pooled urine sample (containing urine from 5 individ-
uals) was analysed by MALDI with/without desalting and
by SELDI on 3 ProteinChip array surfaces. The resulting
spectra are shown in Figure 1. The MALDI spectra without
de-salting contained 48 peaks in the m/z 1,500–20,000Proteome Science 2008, 6:19 http://www.proteomesci.com/content/6/1/19
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range with a signal to noise ratio greater than 5. De-salting
increased this to 63 peaks. Q10 and CM10 ProteinChip
Arrays were prepared at pH 7 and produced 46 and 53
peaks respectively. The IMAC chip produced 67 peaks
between m/z 1500 and 20,000. In this preliminary work
MALDI spectra were acquired up to m/z 200,000, how-
ever, they contained very little information above m/z
15,000 whereas the SELDI spectra contained a number of
peaks in the m/z 20,000–200,000 range.
MALDI Profiling Results
MALDI spectra were acquired in triplicate on diluted urine
samples (20 μg protein/ml). Following total ion current
normalisation, 101 peaks with a signal to noise ratio
greater than 5 were detected between m/z 1500 and
20,000. The mean coefficient of variation (CV) of peak
intensity for peaks with intensity >5 and <30 in the QC
sample was 22% (a pooled urine sample analysed at 30
random positions during the experiment). We tested for
significant differences in peak intensity between the non-
cancer controls and the colorectal cancer patients using
two-sample t-tests and multiple linear regressions (LM).
LM was used to confirm that changes in peak intensity
apparently associated with colorectal cancer were not due
to the slight imbalances in age, gender or urinary protein
concentration in our cancer patient and non-cancer con-
trol groups (Table 1). Nine peaks showed up as cancer
related (significant) using a combination of both statisti-
cal tests (p < 0.05) and are shown in Table 2.
MALDI spectra were also acquired in triplicate following
concentration and de-salting on C8 magnetic beads
(MALDI-DS). We detected 97 peaks with a signal to noise
ratio greater than 5 between m/z 1500 and 20,000. The
mean CV of peak intensity for peaks with intensity >5 and
<30 in the QC sample spectra was 20%. Five peaks
attained significance in both t-tests and LM (Table 2). The
most significant peak at m/z 2193 is, on average, halved
MALDI and SELDI spectra Figure 1
MALDI and SELDI spectra. Spectra obtained from a pooled urine sample. A: MALDI without desalting, B: MALDI with desalt-
ing, C: CM10 ProteinChip array, D: Q10 ProteinChip array, E: Cu2+ loaded IMAC30 ProteinChip array.
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in intensity in the cancer patients and was also signifi-
cantly decreased in the data obtained without de-salting.
SELDI Profiling Results
Duplicate spectra were acquired for each sample over m/z
1500–20,000 and 20,000–200,000 ranges. One hundred
peaks were detected in the low mass range and a further
35 peaks were detected in the high mass range. The mean
CV of peak intensity for peaks with intensity >5 and <30
in the QC sample spectra was 29%. The intensities of 6
peaks were significantly associated with cancer patients
according to t-tests and LM (Table 2).
Comparison of MALDI and SELDI profiling
All 3 profiling methods produced spectra with ~100 peaks
between m/z 1500 and 20,000. Figures 2a–d show
expanded views of regions of the MALDI, MALDI-DS and
SELDI spectra from one urine sample: some peaks are
present in both MALDI methods but not SELDI (eg Fig 2a)
whereas other peaks are better detected by SELDI than
MALDI (e.g. the 11.7 kDa peak of β2-microglobulin in Fig
2d). The redundancy between the profiling methods can
be estimated if one assumes that peaks falling within a m/
z window of 0.3% in the 3 datasets represent the same
molecular ion (Figure 3). Approximately 72% of peaks are
shared between the MALDI and MALDI-DS datasets
whereas redundancy between the MALDI datasets and the
SELDI is <40%. If a peak is detected in 2 or more datasets
then a strong correlation between the intensities in the
datasets might be expected and we find this to be the case
for many peaks (examples shown in Figure 4). We find a
positive correlation between the intensities of all peaks
shared between the MALDI datasets with an average cor-
relation coefficient of 0.61 (range 0.2–0.87). The correla-
tions between MALDI and SELDI datasets are not as
strong with an average correlation coefficient of 0.44
(range -0.13–0.85) and 18 out of 39 peaks having a corre-
lation coefficient >0.50. For 9 of the 39 shared peaks
within a 0.3% m/z window little or no correlation existed
(correlation  coefficient <0.2).
Class Prediction Models
LR was used to discriminate between non-cancer controls
and cancer patients based on the peaks in their urine pro-
files. The variables used in this analysis were the combina-
tions of proteins (or their transformations) selected by
MFP from among those found to be cancer related. The
sensitivities and specificities estimated by leave-one-out
cross-validation are shown in Table 3: all 3 datasets pro-
vided some level of discrimination with the MALDI data-
set producing the best classifier with 65% sensitivity at
84% specificity. A model built using the significant peaks
from all 3 datasets selected peaks with m/z ratios of 1606,
2051 and 5011 (MALDI) and 4758 (MALDI-DS) as dis-
criminators and yielded 78% sensitivity and 87% specifi-
city. The models built on MALDI, MALDI-DS, SELDI
datasets and a combination of these datasets correctly
detected 65%, 63%, 48% and 70% of the early stage can-
Table 2: Cancer associated MALDI/SELDI peaks.
Method m/z P value (t-test) P value (LM) Fold change AUROC
MALDI 1606* 0.0001 0.0006 0.72 0.71
MALDI 2051* 0.0253 0.0338 1.20 0.64
MALDI 2195* 0.0027 0.0373 0.67 0.65
MALDI 2254* 0.0023 0.0030 1.24 0.69
MALDI 4169* 0.0074 0.0083 1.25 0.65
MALDI 5011 0.0068 0.0009 1.23 0.68
MALDI 5239* 0.0009 0.0002 1.31 0.68
MALDI 11025* 0.0186 0.0430 0.48 0.60
MALDI 11400* 0.0146 0.0133 0.44 0.59
MALDI-DS 2193* 0.0001 0.0001 0.53 0.70
MALDI-DS 2758* 0.0029 0.0029 0.74 0.64
MALDI-DS 4758* 0.0121 0.0408 0.70 0.64
MALDI-DS 5812* 0.0052 0.0070 0.59 0.63
MALDI-DS 6250 0.0426 0.0108 1.22 0.60
SELDI 1885 0.0153 0.0450 1.28 0.64
SELDI 6086* 0.0259 0.0050 1.14 0.61
SELDI 11750* 0.0019 0.0032 1.67 0.67
SELDI 11960* 0.0005 0.0182 1.65 0.68
SELDI-HR 39480 0.0217 0.043 0.94 0.62
SELDI-HR 53760* 0.0293 0.0150 0.98 0.64
Table 2 shows the m/z ratios, p-values obtained by t-test and multiple linear regression (LM), fold-change (cancer mean intensity/control mean 
intensity) and area under the receiver operator characteristic curve (AUROC) for all peaks which obtained p < 0.05 in both statistical tests. The 
peaks that are significant in one or both statistical tests if only the early stage cancers are compared to the non-cancer controls are marked with an 
asterisk.Proteome Science 2008, 6:19 http://www.proteomesci.com/content/6/1/19
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Comparison of MALDI and SELDI urine profiles Figure 2
Comparison of MALDI and SELDI urine profiles. Figures 2 a-d show expanded regions of the MALDI, MALDI-DS and SELDI 
spectra from one female non-cancer subject.
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cers (Duke's stages A & B) indicating that, as suggested by
our statistical analysis (Table 2), the proteomic changes
are not confined to late stage disease. ROC curves for the
models built on the 3 datasets are shown in Figure 5.
Polypeptide Identifications
We have determined the identity of 4 of the peaks most
significantly associated with colorectal cancer. The most
significantly cancer associated peak in the MALDI-DS
experiment with a m/z ratio of 2193 is decreased in inten-
sity in the cancer patients and is also significantly
decreased in the MALDI experiment (m/z 2195, Table 2).
This is a prominent peak in urine spectra whose identity
has previously been described in the literature as hepci-
din-20 (along with hepcidin-22 and hepcidin-25 at m/z
2433 and 2788) [31]. We gained strong support for the m/
z 2193 peak arising from hepcidin-20 by obtaining an
accurate m/z value for the monoisotopic H+ ion underly-
ing this peak using an orthogonal time-of-flight MALDI
mass spectrometer (ProTOF 2000). The accurate m/z
value (2190.838) matches the calculated m/z of hepcidin-
20 corrected for the 4 internal disulphide bridges in the
structure (2190.840). Additionally, the mass of the peak
increases by 464.2 Da when treated with DTT and iodoac-
teamide, again consistent with 4 disulphide bridges (data
not shown). We have identified the SELDI peaks elevated
in cancer at m/z 11720 and 11920 as β2-microglobulin
from 3 tryptic fragments giving 23% sequence coverage
(the 11920 peak is probably a sinapinic acid adduct as this
is absent when α-cyano-hydroxycinnamic acid is used as
the matrix, data not shown). This identification was con-
firmed using an immuno-MS approach (Figure 6). A sec-
ond peak elevated in the cancer patients in the SELDI
survey at m/z 1885 was identified as a fragment of the α-
chain of fibrinogen (DEAGSEADHEGTHSTKRG). This
identification is based on LC-ESI-MS/MS of the purified
'peak' without prior tryptic digestion. The same MS/MS
data and database match were obtained in several repeat
experiments. We have not attempted to confirm this iden-
tification by immuno-MS as the 1885 peak represents
such a small portion of fibrinogen but have obtained an
accurate monoisotopic H+ m/z of 1883.816 (predicted
1883.811) Additionally, a synthetic version of this pep-
tide produced identical MS and MS/MS data (Figure 7).
Independent quantification of the identified polypeptides
Synthetic versions of the DEAGSEADHEGTHSTKRG
fibrinogen peptide with/without 13C/15N alanine and gly-
cine residues (average H+ ion m/z values of 1885 and
1899) were synthesised by AltaBioscience, University of
Birmingham. Figure 8a shows MALDI spectra of a urine
sample devoid of the endogenous peak spiked with 0.5
μg/ml heavy peptide and increasing concentrations of
light peptide. The concentration of the light peptide can
be calculated from the ratio of the peak heights at m/z
1885 and 1899 and the concentration of heavy peptide in
the sample. In the experiment shown in Figure 8b we
added 0.5 μg/ml heavy peptide and varying concentra-
tions of light peptide to 3 urine samples low in the endog-
enous 1885 peak. There is close agreement between the
concentration of light peptide and the concentration cal-
culated from the MALDI peak heights. This experiment
worked equally well on IMAC chips (data not shown).
Figure 8c shows the correlation (r = 0.607) between the
height of the 1885 peak in MALDI spectra following total
ion current normalisation and the concentration of the
DEAGSEADHEGTHSTKRG peptide (calculated from the
ratio of the 1885 and 1899 peak heights) in the urine of
colorectal cancer patients and non-cancer controls. We
find that, as with the peak intensity in the profiles, the
concentration of this peptide (as calculated by the
labelled peptide spiking approach) is significantly ele-
vated in the colorectal cancer patients at 183 ± 117 ng/ml
versus 117 ± 54 ng/ml (mean ± SD, t-test p = 0.0005).
Labelled hepcidin-20 was synthesised with a 13C/15N phe-
nylalanine residue (Δ mass = 10 Da, giving 2202 Da),
incubated overnight at room temperature in 6 M urea, 100
mM ammonium bicarbonate to allow disulphide bridge
Overlap between SELDI and MALDI datasets Figure 3
Overlap between SELDI and MALDI datasets. This Venn dia-
gram shows the number of peaks detected in urine between 
m/z 1500 and 20,000 by MALDI, MALDI-DS and SELDI and 
the overlap between the 3 methods.
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formation and purified by RP-HPLC. Correct folding/
disulphide bridge formation was surmised from an 8 Da
reduction in mass and amide proton NMR shifts consist-
ent with published structures (data not shown) [32,33].
The folded labelled hepcidin-20 was then spiked in to
urine samples prior to desalting on C8 beads and acquisi-
tion of MALDI mass spectra. Hepcidin-20 concentrations
were then determined from the ratio of peak intensities at
m/z 2192 and m/z 2202. MALDI spectra showing the
endogenous hepcidin-20 and labelled hepcidin-20 peaks
in 5 urine samples spiked with 80 ng/ml labelled hepci-
din-20 are shown in Figure 9a. Figure 9b shows the rela-
tionship between the hepcidin-20 peak intensity in the
MALDI-DS experiment and the concentration calculated
Correlation between peak intensities in different datasets Figure 4
Correlation between peak intensities in different datasets. Figure 4 shows the correlations between peak intensities in the 
MALDI and MALDI-DS and MALDI and SELDI datasets for 2 peaks: m/z 2193 (A & B) and m/z 4258(C & D).
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from the m/z 2192/2202 ratio (r = 0.568). The mean hep-
cidin-20 concentration in the cancer patients is lower than
that of the non-cancer controls (30.2 ± 9.1 versus 39.6 ±
12.5 ng/ml), however this is not statistically significant (p
= 0.132).
The relationship between the SELDI peak at m/z 11750
and β2-microgobulin concentration determined by ELISA
is shown in Figure 10. There is strong positive correlation
(r = 0.656) and the mean concentration in the cancer
patients is significantly higher than in the non-cancer con-
trols (5.90 ± 7.08 versus 3.46 ± 4.42 μg/ml, p = 0.018).
Discussion
We have used three profiling methods to characterise pro-
teomic differences between the urine of colon cancer
patients and non-cancer controls. Although no peaks were
found to be unique to either the cancer patients or con-
trols a number of changes in peak intensity were signifi-
cantly associated with colon cancer and these, in
conjunction with class prediction models, yielded a diag-
nostic sensitivity of 78% and specificity of 87%. These val-
ues are higher than those obtained with serum CEA but
not as good as those obtained in similar profiling studies
conducted on serum and the number and significance of
proteomic changes in urine also appear to be less than in
serum [6,14,15]. Although the reduction in concentration
of abundant serum proteins in urine relative to serum
Receiver operator characteristic analysis of classification  models Figure 5
Receiver operator characteristic analysis of classification 
models. The MALDI model is represented as a dot-dash line 
with solid symbols, the MALDI-DS model as a dotted line 
with open triangles, the SELDI model as a dashed line with 
open circles and the 'ALL' model as a solid line with solid 
symbols (the diagonal represents no discrimination).
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Table 3: Class Prediction Model Results.
Dataset Sensitivity Specificity Misclassification Rate AUROC
MALDI 65 (52–78) 84 (75–93) 24 0.80
MALDI-DS 68 (55–80) 68 (57–79) 32 0.67
SELDI 51 (38–64) 75 (64–86) 34 0.69
ALL 78 (66–90) 87 (78–96) 17 0.88
Table 3 summarises the logistic regression models tested by leave-one-out cross-validation. Sensitivity, specificity and misclassification rate are 
presented as percentages (95% confidence intervals). The m/z values of the peaks used in the logistic regressions are, MALDI: 1606, 2254, 5011, 
MALDI-DS: 2193, SELDI: 1885 and 11960, ALL: 1606, 2251, 4758, 5011. Number of samples in each dataset: MALDI: 123 (55 cancer), MALDI-DS: 
119 (53 cancer), SELDI: 116 (55 cancer).
β2-microglobulin immuno-MS Figure 6
β2-microglobulin immuno-MS. Panel A shows the IMAC-
SELDI spectrum of neat serum, panel B the spectrum of the 
same serum following depletion with protein G beads loaded 
with rabbit polyclonal anti-serum to human β2-microglobulin 
(Sigma M8523) and panel C the spectrum of the eluted β2-
microglobulin.
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Fibrinogen peptide MS/MS data Figure 7
Fibrinogen peptide MS/MS data. Figure 7a shows one of the MS/MS spectra used to identify the m/z 1885 SELDI peak as the 
fragment of fibrinogen DEAGSEADHEGTHSTKRG (3+ parent ion, 1+ fragments). Figure 7b shows MS/MS analysis of synthetic 
DEAGSEADHEGTHSTKRG. Figure 7c shows MS/MS analysis of synthetic DEAGSEADHEGTHSTKRG with 13C + 15N labelled 
alanine at positions 3 and 7 and glycine at positions 4 and 11. All spectra obtained by LC-MS/MS as described in the Methods 
section.
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should aid detection of more informative lower abun-
dance species, urine is one step further removed from the
tumour than blood and may have a more variable compo-
sition.
We find that, although the 3 profiling methods used here
are complimentary (Figure 3) the simplest method,
MALDI, found the most cancer associated proteomic
changes and produced the best single method classifier.
Spiking of stable isotope labelled fibrinogen peptide into urine samples Figure 8
Spiking of stable isotope labelled fibrinogen peptide into urine samples. Panel A shows the MALDI spectra of a urine sample 
spiked with 0.5 μg/ml heavy peptide and 0, 0.3, 0.7 and 1 μg/ml light peptide. Panel B plots the 'measured' concentration of light 
peptide against the actual concentration added (3 experiments in different urine samples devoid of the endogenous peptide). 
Panel C plots MALDI peak height at m/z 1885 for each sample in the study against 'measured' concentration (from the light/
heavy peptide peak intensity) with non-cancer controls indicated by solid triangles and cancer patients by open squares.
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Determination of urinary hepcidin-20 by comparison to stable isotope labelled hepcidin-20 Figure 9
Determination of urinary hepcidin-20 by comparison to stable isotope labelled hepcidin-20. All urine samples were diluted to 
20 μg protein/ml and spiked with labelled hepcidin-20 prior to desalting on C8 beads and MALDI mass spectrometry. Figure 9a 
shows spectra of 5 urines with increasing levels of endogenous hepcidin-20 (m/z 2192) spiked with 80 ng/ml labelled hepcidin-
20 (m/z 2202). Figure 9b shows the correlation between the hepcidin-20 concentrations determined from spiked experiments 
and the peak intensities in the original MALDI-DS experiment. Non-cancer controls are indicated by solid triangles and cancer 
patients by open squares.
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Both MALDI-DS and SELDI involve a binding step with
selectivity for certain peptides which, by chance, excluded
some of the polypeptides of interest. The MALDI-DS data
gave marginally better reproducibility than MALDI
whereas the SELDI data showed the highest variability of
the 3 methods (probably partly due to the concentration
of protein at the binding step being sub-optimal when
using urine for SELDI) possibly masking some effects of
cancer on the urinary proteome. When MFP was applied
to all of the significant peaks from the 3 methods, peaks
from both the MALDI and MALDI-DS datasets were
selected to generate a classifier that performed better than
that based on the MALDI data alone (Table 3 and Figure
5).
It is challenging to identify all of the peaks of interest in
SELDI/MALDI profiling work for a range of reasons: we
attempted to identify the discriminatory peaks with m/z
ratios of 1606, 2051 and 5011. The m/z 1606 peak proved
difficult to purify or obtain MS/MS data on. The m/z 2051
peak gave good MS/MS data but we were unable to obtain
a database match and the m/z 5011 peak, although suc-
cessfully purified, did not appear to generate identifiable
tryptic peptides. Furthermore digestion using Asp-N, Glu-
C, Lys-C or Arg-C failed to generate identifiable peptides.
However we did successfully identify the polypeptides
responsible for discriminatory peaks at m/z 1885, 2193
and 11,750. This is a prerequisite for both the develop-
ment of alternative assay platforms for candidate biomar-
kers and for understanding the mechanisms underlying
these proteomic changes. The cancer associated proteins
that we have identified are hepcidin-20, β2-microglobulin
and a 18 residue fragment of the α-subunit of fibrinogen.
All 3 are proteins primarily synthesised in the liver and are
likely to reflect secondary effects of cancer rather than
direct secretion/leakage from the tumour itself. Hepcidin-
20, decreased in the urine of cancer patients, is an N-ter-
minally truncated form of the hormone hepcidin-25
which is elevated by iron overload and inflammation
[34]. Hepcidin-25 which is involved in iron homeostasis
(which may be linked to colorectal cancer [35]) is not sig-
nificantly different in the urine of the cancer patients and
non-cancer controls although we did find a positive corre-
lation with T stage [36]. The intensities of the peaks corre-
sponding to β2-microglobulin are, on average, elevated in
the urine of the colorectal cancer patients. Serum levels of
β2-microglobulin are known to be elevated during infec-
tion and in certain lymphoid malignancies [37]. We have
previously detected β2-microglobulin as slightly increased
in the serum of hepatocellular carcinoma and colorectal
cancer patients [6,30]. It is attractive to link the increased
urine β2-microglobulin concentration with the elevated
serum concentration (although it could also be caused by
decrease tubular reabsorbtion). The m/z 1885 peak corre-
sponding to a 18 residue fragment of fibrinogen is present
in non-cancer controls, but has an increased intensity in
the colorectal cancer patients. Several proteomic profiling
studies have now associated proteolytic fragments of
abundant serum proteins with malignant disease [38,39].
Thus the increase in the level of fibrinogen fragment, pre-
sumably generated in the blood, may arise from increased
proteolytic activity or increased total fibrinogen levels
(elevated fibrinogen has been reported in the serum of
colorectal cancer patients [40]).
As SELDI and MALDI are not quantitative techniques we
have used alternative assays to test whether the cancer
associated changes in intensity of the MALDI/SELDI peaks
of the 3 identified polypeptides truly reflect changes in
concentration. Antibodies specific for the 1885 Da frag-
ment of fibrinogen and hepcidin-20 do not exist so we
spiked stable isotope labelled versions of these peptides in
to samples prior to MALDI mass spectrometry. These
internal standards should behave in an identical manner
to the endogenous peptides during sample preparation
and ionisation and enable peptide concentration determi-
nation regardless of inter-sample influences on the mass
spectra. β2-microglobulin was determined by ELISA. For
all 3 polypeptides a strong positive correlation (r>0.5)
was found between MALDI/SELDI peak height and con-
centration indicating that peak heights can, in many cases,
be used as an indicator of relative concentration. For one
of the three polypeptides, hepcidin-20, the association
with cancer lost statistical significance when the concen-
tration was determined relative to the stable isotope
standard. This, perhaps unsurprisingly, suggests that sta-
Correlation between SELDI peak intensity at m/z 11750 and  β2-microglobulin concentration Figure 10
Correlation between SELDI peak intensity at m/z 11750 and 
β2-microglobulin concentration. The β2-microglobulin was 
determined in urine samples diluted to 20 μg protein/ml 
using a sandwich ELISA (Demeditec Diagnostics GmbH, DE-
05BM). Non-cancer controls are indicated by solid triangles 
and cancer patients by open squares.
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tistically significant changes in proteomic profiling exper-
iments will not always yield useful biomarkers.
Even with effective screening tools such as faecal occult
blood testing, that are now entering routine clinical prac-
tice, large numbers of 'false-positive' results will be gener-
ated, i.e. the faecal occult blood test is of low specificity
and the requisite, more specific follow-up examinations
such as colonoscopy represent a significant health care
burden. If our preliminary figures for sensitivity can be
improved it is conceivable that proteomic analysis of
urine might, by identifying those with a low probability of
having tumours, permit prioritisation of investigation to
those at highest risk. What is more, the detectable cancer
associated proteomic changes in urine may compliment
those detected in serum [6] and a combined analysis
might improve both sensitivity and specificity for early
disease diagnosis.
Conclusion
The experiments presented here show that colon cancer
causes changes in the urinary proteome that can be used
to discriminate between non-cancer controls and patients
with early stage colorectal cancer. We find that, although
there is considerable overlap between the 2 MALDI meth-
ods and the IMAC SELDI data, all 3 profiling methods
detect unique peaks. It would be insightful to collect
serum and urine from larger cohorts of non-cancer con-
trols and colorectal cancer patients and to analyse the pep-
tidome and proteome in depth to fully assess the
diagnostic potential of these proteomic changes.
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